RESUMEN
OBJECTIVES: This study focused on PTEN and Livin expression and associations with malignancy in human renal clear cell carcinomas (RCCC). METHODS: PTEN and Livin expression was assessed in 100 RCCC tissue samples, 50 paracarcinoma cases, and 20 normal renal tissue samples using the immunohistochemical Streptavidin proxidase (SP) method. The relationships between binding and corresponding biological characteristics, such as histological grade, lymph node metastases, and clinical stages were analyzed. RESULTS: Positive PTEN expression in RCCC was significantly lower than in renal tissue adjacent to carcinoma tissue and normal renal tissue (P<0.01). Livin expression in the renal tissue adjacent to the carcinoma and normal renal tissues exhibited only low levels, whereas overall Livin expression in RCCC was statistically significant (P<0.01). In RCCC, PTEN expression rate gradually decreased with an increase in clinical stage, whereas that of Livin increased to statistically significant levels (P<0.01), PTEN and Livin levels being negatively correlated (r=-0.395, P<0.01). CONCLUSIONS: PTEN and Livin are important in RCCC development. The two factors combined are expected to provide indices for estimating RCCC malignancy and progression levels, as well as references for RCCC diagnosis and treatment.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/metabolismo , Carcinoma de Células Renales/metabolismo , Proteínas Inhibidoras de la Apoptosis/metabolismo , Neoplasias Renales/metabolismo , Proteínas de Neoplasias/metabolismo , Fosfohidrolasa PTEN/metabolismo , Proteínas Supresoras de Tumor/metabolismo , Proteínas Adaptadoras Transductoras de Señales/inmunología , Adulto , Anciano , Anticuerpos Monoclonales/inmunología , Carcinoma de Células Renales/genética , Carcinoma de Células Renales/patología , Femenino , Regulación Neoplásica de la Expresión Génica , Humanos , Inmunohistoquímica , Proteínas Inhibidoras de la Apoptosis/inmunología , Neoplasias Renales/genética , Neoplasias Renales/patología , Masculino , Persona de Mediana Edad , Proteínas de Neoplasias/inmunología , Fosfohidrolasa PTEN/inmunología , Proteínas Supresoras de Tumor/inmunología , Dedos de ZincRESUMEN
OBJECTIVE: To study the sexual function of men with benign prostatic hyperplasia (BPH) with the lower urinary tract symptoms (LUTS) and the effect of Tamsulosin. METHODS: One hundred and ninety-two cases of BPH accompanied with typical LUTS were investigated using the International Prostate Symptom Score (IPSS), Quality of Life (QOL), International Index of Erectile Function 5 (IIEF-5) and measuring the flow rate of urine before treatment. The patients were randomly divided into two groups, the treatment group (n = 103) given Tamsulosin 0.2 mg, and the control group (n = 89) taking placebo once a day for 8 weeks. The influence of various factors on sexual function was analyzed before and after treatment. RESULTS: The mean scores of IPSS, QOL, Qmax and IIEF-5 were (20.20 +/- 6.81), (4.51 +/- 0.76), (9.60 +/- 8.79) ml/s and (9.80 +/- 8.62), respectively. The incidence of erectile dysfunction was 75% (144/192). There was statistically significant correlation between age and IPSS score (r = 0. 203, P < 0. 005) or IIEF-5 score (r = -0.571, P < 0.001) as well as between IPSS and IIEF-5 scores (r = - 0.312, P < 0.001). Various indexes were significantly improved after Tamsulosin treatment as compared with pre-treatment (P < 0.001) and placebo administration (P < 0.001), but no significant difference in various indexes was observed in the control group. CONCLUSION: Age and LUTS are dangerous factors for sexual function, and the severity of LUTS is closely related to the development of sexual dysfunction. Tamsulosin can at once improve the sexual function and the lower urinary tract symptoms of the BPH patients.